Gastroenterology

Back to articles

Digestive Disease Week Features Variety of Important Advances

KEY POINT

Among the more than 5,000 abstracts presented last month at Digestive Disease Week in New Orleans were important studies on use of tegaserod (Zelnorm—Novartis) for upper gastrointestinal symptoms of functional heartburn; adalimumab (Humira—Abbott), natalizumab (Antegren—Biogen Idec; Elan [investigational]), and sargramostim (Leukine— Berlex) for Crohn’s disease; and PEG-interferon alpha for acute cases of hepatitis C infection.

SOURCES

Rodriguez-Stanley S et al. Tegaserod significantly improves esophageal mechanical pain threshold, regurgitation and global preference vs placebo in patients with functional heartburn. Presented at Digestive Diseases Week, New Orleans, La., May 19, 2004.

Hanauer S et al. A randomized, double-blind, placebo-controlled trial of the human anti-TNF-alpha monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease. Presented at Digestive Diseases Week, New Orleans, La., May 19, 2004.

Sandborn W et al. A phase III, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of Antegren (natalizumab) in maintaining clinical response and remission in Crohn’s disease (ENACT-2). Presented at Digestive Diseases Week, New Orleans, La., May 19, 2004.

Korzenik J et al. Duration of sargramostim effects in patients with moderately-to-severely active Crohn's disease (CD): follow-up results from a randomized, double-blind, placebo-controlled trial. Presented at Digestive Diseases Week, New Orleans, La., May 19, 2004.

Kamal SM et al. Peginterferon alpha therapy in acute hepatitis C prevents chronicity and enhances hepatitis C virus-specific T-cell responses [abstract]. Presented at Digestive Diseases Week, New Orleans, La., May 16, 2004.